Search
International Association Against Painful Experiments on Animals

History of Animal Experiments

19: References

References: 1) L.E. Davis, Journal of the American Veterinary Medical Associations, 1979, vol. 175, 1014-1015. 2) An Introduction to the Study of Experimental Medicine, C. Bernard, 1865 (translation of the original text by H. C. Green) (Dover Publications Inc., 1957). 3) Lancet, 1909, March 20, 848-849. 4) R. Koch, British Medical Journal, 1884, September 6, 454. 5) C. T. Dollery in Risk-Benefit Analysis in Drug Research, Ed. J. F. Cavalla (MTP, 1981). 6) S. Irwin, Science, 1962, April 13, 123. 7) F. I. McMahon, Medical World News, 1965, vol. 6, 168. 8) S. R. Walker & J. A. Parish in Trends and Changes in Drug Research and Development, Eds. B. C. Walker & S. R. Walker (Kluwer Academic Publishers, 1988). 9) J. T. Litchfield Jnr., Clinical Pharmacology & Therapeutics, 1962, vol. 3, 665-672. 10) D. Salsburg, Fundamental & Applied Toxicology, 1983, vol. 3, 63-67. 11) Farlutal promotional literature (Farmitalia Carla Erba); Diane promotional literature (Berlimed Pharmaceuticals). 12) D. M. Davies (Ed.), Textbook of Adverse Drug Reactions (Oxford University Press, 1977). 13) A. Rowan, Of Mice, Models and Men, (State University of New York, 1984). 14) D. V. Parke & R. L. Smith (Eds), Drug Metabolism -from Microbe to Man (Taylor & Francis, 1977). 15) G. N. Volans in The Contribution of Acute Toxicity Testing to the Evaluation of Pharmaceuticals, Eds. D. Schuppan, A. D. Dayan & F. A. Charlesworth (Springer-Verlag, Berlin, 1986). 16) G. T. Okita, Federation Proceedings, 1967, vol. 26, 1126. 17) F. Coulston & D. Serrone, Annals of the New York Academy of Science, 1969, vol. 162, 681-706; see also reference 18. 18) D. W. Swanston in Animals and Alternatives in Toxicity Testing, Eds. M. Ball, R. J. Riddell & A. N. Worden (Academic Press, 1983). 19) M. H. Briggs in Biomedical Research Involving Animals, Eds. Z. Bankowski & N. Howard-Jones (Council for International Organisations of Medical Sciences, 1984). 20) R. M. Ward & T. P. Green, Pharmacology & Therapeutics, 1988, vol. 36, 326. 21) S. Kalsner, Journal of Physiology, 1985, vol. 358, 509-526. 22) Lancet, 1987, May 2, 1016. 23) P. Newmark, Nature, 1989, October 19, 566-567. 24) J. Collier & A. Herxheimer, Lancet, 1987,January 10, 113-114. 25) R. D. Mann, Modern Drug Use, an Enquiry on Historical Principles, (MTP, 1984). 26) S. J. Alcock, Proceedings of the European Society for the Study of Drug Toxicity, 1971, vol. 12, 184-190. 27) C. Spriet-Pourra & M. Auriche, Drugs Withdrawn from Sale (PJB Publications, 1988). 28) New Scientist, 1980, July 17,218. 29) W. H. Inman in Monitoring for Drug Safety, Ed. W. H. Inman (MTP, 1980). 30) R. Sharpe, The Cruel Deception (Thorsons, 1988) and references therein. 31) A. P. Fletcher, Journal of the Royal Society of Medicine, 1978, vol. 71,693-698. 32) T. Koppanyi & M. A. Avery, Clinical Pharmacology & Therapeutics, 1966, vol. 7, 250-270. 33) M. Weatherall, Nature, 1982, April 1, 387-390. 34) B. Brodie, Clinical Pharmacology & Therapeutics, 1962, vol. 3, 374-380. 35) R. Doll, Cancer, 1980, vol. 45, 2475-2485. 36) J. C. Bailar & E. M. Smith, New England Journal of Medicine, 1986, vol.314, 1226-1232. 37) C. S. Muir & D. M. Parkin, British Medical Journal, 1985, January 5, 5-6. 38) D. F. N. Harrison, Clinical Oncology, 1980, vol. 6, 1-2. 39) W. P. U. Jackson & A. I. Vinik, Diabetes Mellitus (Edward Arnold, 1977). 40) R. Levine, introduction to B. W. Volk & K. F. Welman, The Diabetic Pancreas (Tindall, 1977). 41) F. T. Gross et al, Health Physics, 1989, vol. 56, 256. 42) E. Rubin & C. S. Lieber, New England Journal of Medicine, 1974, vol.290, 128-135. 43) C. C. Ainley et al, Journal of Hepatology, 1988, vol. 7, 85-92. 44) J. V. Jones et al, Journal of Hypertension, 1988, vol. 6, 419-422. 45) B. Everill & M. S. Berry, Physiology & Behaviour, 1987. vol. 39, 45-51. 46) Science, 1985, December 20, 1355-1358. 47) Scrip, 1987, January 16,30. 48) H. Eagle & G. E. Foley, American Journal of Medicine, 1956, 739-749. 49) G. M. L. Gyte&J. R.B.Williams, ATLA, 1985, vol. 13.38-47. 50) J. W. Lash & L. Saxen, Nature, 1971, August 27, 634-635. 51) See Mutagenesis, 1989, vol. 4 for several examples. 52) E. Heilbron, Toxicology, 1980, vol. 17, 269-272. 53) For example, C. N. D. Cruickshank & E. J. L. Lowbury, British Medical Journal, 1952, November 15, 1070-1072; M. Albrecht, Arzneimittel-Forschung, 1962, no.3, 282-285; G. Corrssen et al, Anesthesiology, 1966, vol. 27, 155-162. 54) J. Marx, Science, 1990. February 16, 809. 55) B. B. Brodie, Acceptance Speech, Torald Sollaman Award, Meeting of the American Society for Pharmacology & Experimental Therapeutics, Fall 1963. 56) F. D. A. Drug Review: Postapproval Risks 1976-1985 (U.S. General Accounting Office, April 1990).

 

More >> 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  

 


© IAAPEA 2017

Site design by Brit-net